PD-1阻断剂治疗是晚期食管癌（EC）最有前途的治疗方法，因此研究与治疗相关的不良事件（TRAEs）的相应毒性很关键。我们进行了系统综述和荟萃分析，以探索EC中不同PD-1阻断剂治疗的毒性剖面。共包括来自10项临床试验的5595名患者，所有级别TRAEs的总体发生率为88％（95％ CI 72.0-95.0），PD-1单一阻断、PD-1阻断与化疗、双重阻断组的3级或更高级别TRAEs的发生率分别为24.0％（15.0-36.0）、64.0％（56.0-71.0）和34.2％（29.1-39.7）。与化疗相比，接受PD-1阻断剂治疗的TRAEs总体级别RR为0.96（93.0-100.0），3级或更高级别TRAEs的RR为0.75（60.0-94.0）。我们提供了关于PD-1阻断剂方案的毒性全面的统计数据，为临床医生提供了有用的参考。 版权所有©2023 Elsevier B.V.。

PD-1 blockade-based therapies are the most promising treatment for advanced esophageal cancer (EC). It is crucial to investigate the corresponding toxicity profiles of treatment-related adverse events (TRAEs). We conducted a systematic review and meta-analysis to explore toxicity profiles across different PD-1 blockade-based treatments in EC. A total of 5595 patients from 10 clinical trials were included. The overall rates of TRAEs were 88 % (95 % CI 72.0-95.0), 98.0 % (97.0-99.0), and 79.5 % (74.6-83.7) for all grade TRAEs, 24.0 % (15.0-36.0), 64.0 % (56.0-71.0), and 34.2 % (29.1-39.7) for grade 3 or higher TRAEs in PD-1 blockade alone, PD-1 blockade plus chemotherapy, and dual blockade group, respectively. Compared to chemotherapy, RRs for patients receiving PD-1 blockade-based treatments for all grade TRAEs were 0.96 (93.0-100.0) and 0.75 (60.0-94.0) for grade 3 or higher TRAEs. We exhibited comprehensive statistics on the toxicity of the PD-1 blockade-based regimens, providing useful references for clinicians.Copyright © 2023 Elsevier B.V. All rights reserved.